GNLX Company Profile and Key Details

Genelux Corporation (NASDAQ:GNLX) closed at $2.80 USD, losing -$0.05 (-1.75%) from the previous close of $2.85. The stock is currently mid-range between its 52-week high and low $2.29 and $8.54. With a market capitalization of about $105.33 million, Genelux Corporation is classified as a micro-cap and shows lower-than-market volatility (beta ~0.50). Key stats such as the average daily volume over the past year has been around 189.33 thousand shares, in line with its 52-week average. Headquartered in Westlake Village, CA, Genelux Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Thomas D. Zindrick, the company employs approximately 24 people and listed since January 26, 2023. Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

GNLX has shown mixed momentum, gaining 3.02% over the past week and -52.27% over the past quarter, though year-to-date performance is down -37.39%. Short-term trend indicators are bullishly aligned (SMA20 10.26%, SMA50 -8.08%, SMA200 -24.95%). The stock’s 14-day RSI is 53.17 (neutral), while the ATR of 0.19 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -66.14% below its high and over 45.41% above its low. Average 10-day trading volume of 196.12 thousand shares is in line with the 3-month average of 187.13 thousand, indicating normal recent market interest.

Genelux Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.10. This means the shares are trading above this model’s fair value.

Genelux Corporation generated EPS of -$0.88 over the past year. Five-year average earnings growth is -14.03%. Wall Street analysts project EPS growth of 2.61% annually over the next five years. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.22. Next year's EPS is expected at $17.38. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $10.00. The high target offers 614.29% upside. The low target suggests 257.14% downside. The mean target is $15.33. This offers 447.5% upside. Genelux Corporation earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 11.11%. The prior quarter beat by 9.09%. Over the last six quarters, Apple has recorded several small beats. These include 52.94% in March 28, 2025.

Genelux Corporation has 37.77 million shares outstanding. The public float is 33.30 million shares, elevated short interest at 5.69% of float. This equals 2.11 million shares. The short ratio is 14.24 days. Institutional investors hold 22.65% of the float. Insiders own 13.24%. Szalay Aladar holds 599.82 thousand shares, Zindrick Thomas has 532.05 thousand shares and Thomas John has 482.78 thousand shares. Over the past six months, insider transactions show net selling. They sold 30.42 thousand shares across 12 transactions.